Finance

Lists
MRCK34:BVMF
Merck BDR
R$100.80
0.00%
(0.00) 1D
Nov 6, 5:54:30 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for MRCK34...
Open
R$100.70
High
R$101.11
Low
R$98.70
Mkt. cap
362.01B
Avg. vol.
3.96K
Volume
1.16K
52-wk high
R$104.79
52-wk low
R$55.96
Shares outstanding
2.47B
No. of employees
74K
Open
R$100.70
High
R$101.11
Low
R$98.70
Mkt. cap
362.01B
Avg. vol.
3.96K
Volume
1.16K
52-wk high
R$104.79
52-wk low
R$55.96
Shares outstanding
2.47B
No. of employees
74K
News stories
From web sources and news partners
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck BDR
CEORobert M Davis
Employees74K
FoundedJan 1, 1891
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitemerck.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
16.40B
16.29B
16.61B
18.08B
Cost of goods sold
4.30B
3.88B
4.13B
4.41B
Cost of revenue
4.30B
3.88B
4.13B
4.41B
Research and development expenses
4.00B
3.56B
9.74B
4.54B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.73B
2.57B
2.78B
2.77B
Operating expense
6.73B
6.12B
12.52B
7.30B
Total operating expenses
11.02B
10.00B
16.65B
11.72B
Operating income
5.38B
6.29B
-40.00M
6.37B
Other non operating income
41.00M
42.00M
59.00M
9.00M
EBT including unusual items
3.42B
-3.53B
-683.00M
5.56B
EBT excluding unusual items
4.98B
5.85B
-508.00M
5.82B
Income tax expense
458.00M
709.00M
654.00M
492.00M
Effective tax rate
13.39%
-20.06%
-95.75%
8.85%
Other operating expenses
-
-
-
-
Net income
2.96B
-4.24B
-1.34B
5.06B
Net profit margin
18.07%
-26.03%
-8.04%
28.01%
Earnings per share
2.04
-1.28
-0.13
2.49
Interest and investment income
69.00M
35.00M
35.00M
52.00M
Interest expense
-411.00M
-479.00M
-525.00M
-546.00M
Net interest expenses
-342.00M
-444.00M
-490.00M
-494.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
6.79B
7.69B
1.43B
7.88B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps